1 Background
2 Effects of propofol on breast cancer cells
2.1 Anti-tumor effects
2.2 Pro-tumor effects
Study | Cell line | [Propofol] (μg/ml) | Incubation time (hr) | Proliferation (method) | Migration (method) | Invasion (method) |
---|---|---|---|---|---|---|
Li et al | MDA-MB-231 | 2–10 | 24 | ↓ (wound healing) | ↓ (Matrigel membrane) | |
Ecimovic et al | MDA-MB-231 | 6–10 | 24 | No change (MTT) | ↓ (8 μm pores) | No change (Matrigel membrane, 6 h) |
Ecimovic et al | MCF7 | 4–10 | 24 | No change (MTT) | ↓ (8 μm pores) | ↓ (Matrigel membrane, 6 h) |
Yu et al | a MDA-MB-435 | 2 (10 μM) | 6 | ↓ (TUNEL stain) | ||
Siddiqui et al | MDA-MB-231 | 20 (100 μM) | 24 | ↓ (WST-1) | No change (8 μm pores, 4 h, 5 μg/ml) | |
Garib et al | MDA-MB-468 | 3–9 | 10 | ↑ (collagen matrix, video tracking) | ||
Meng et al | MDA-MB-231 | 2–10 | 12–24 | ↑ (MTT, 10 h) | ↑ (wound healing) |
3 Propofol and the immune system
4 Propofol and postoperative pain management
5 Propofol and clinical trials in breast cancer
Type of Study | Reference | Cancer | Surgery Type | Anesthetic Technique | Number of Patients | Outcome (95% CI) | Estimated Completion Date |
---|---|---|---|---|---|---|---|
Retrospective | Enlund et al. | Breast Cancer | Breast cancer surgery | GA with propofol or sevoflurane | 1873 (620 in propofol and 1217 in sevoflurane) | 3% higher for overall survival at one year in propofol group (p < 0.001) | Finished |
Retrospective | Lee et al | Breast Cancer | Modified radical mastectomy | Propofol-based TIVA or sevoflurane-based anesthesia | 325 (173 in TIVA and 152 in sevoflurane) | Propofol group showed a lower rate of cancer recurrence (p = 0.037) | Finished |
Retrospective | Kim et al | Breast Cancer | Breast Cancer surgery | Propofol-based TIVA or sevoflurane-based anesthesia | 2645 (56 in TIVA and 2589 in volatile--base anesthesia) | No difference | Finished |
Prospective | University of Zurich | Breast Cancer | Breast Cancer surgery | GA with propofol TCI or sevoflurane | 231 | Circulating tumor cells at 3 days after surgery | August, 2017 |
Prospective | Konkuk University Medical Center | Breast Cancer | Breast Cancer surgery | GA with propofol or sevoflurane | 300 | NK cell activity at 1 and 24 h after surgery | July, 2020 |
Prospective | Uppsala University | Breast, colonic and rectal cancer | Breast Cancer surgery | GA with propofol or sevoflurane | 2000 | Overall 5-year survival | December, 2022 |